Cannabinoid-based Drug Discovery and Development Designed to Benefit Cancer Patients

This week in The Onco’Zine Brief Peter Hofland, Ph.D talks with Guy Chamberland, M.Sc., Ph.D, about medicinal cannabis. Chamberland, is a Master Herbalist as well as Chief Executive Officer and Chief Scientific Officer of Tetra Bio-Pharma, a biopharmaceutical company developing cannabinoid-based drugs. Tetra Bio-Pharma has a clinical development program aimed at bringing novel drugs and treatments to patients and their healthcare providers. To do this, the Company has several subsidiaries that are engaged in the development of Bio Pharmaceutical drugs and Natural Health Products containing Cannabis and other medicinal plant based elements. Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis-use with the supporting scientific validation and safety-data required by federal and national regulators, physicians and insurance companies.